Medication (Re)fill adherence measures derived from pharmacy claims data in older Americans: A review of the literature

Drugs and Aging

Volumn 30, Issue 6, 2013, Pages 383-399

  Sattler, Elisabeth Lilian Pia ^a   Lee, Jung Sun ^a   Perri III, Matthew ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIGLAUCOMA AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIPARKINSON AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; GALANTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MUSCARINIC RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PAROXETINE; PHENOBARBITAL; PHENYTOIN; PROTON PUMP INHIBITOR; RALOXIFENE; RISEDRONIC ACID; RIVASTIGMINE; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; BILLING AND CLAIMS; CHRONIC LUNG DISEASE; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPILEPSY; HEART FAILURE; HEART INFARCTION; HORMONAL THERAPY; HUMAN; HYPERTENSION; MEDICARE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN ANGLE GLAUCOMA; OSTEOPOROSIS; OVERACTIVE BLADDER; PARKINSON DISEASE; PATIENT COMPLIANCE; PHARMACY; PRIORITY JOURNAL; SENESCENCE; TREATMENT REFUSAL;

AGED; AGED, 80 AND OVER; ALGORITHMS; DATABASES, FACTUAL; DRUG PRESCRIPTIONS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; MALE; MEDICARE; MEDICATION ADHERENCE; PHARMACIES; UNITED STATES;

EID: 84878644701     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0074-z     Document Type: Article

References (62)

1. US Census Bureau. Percent distribution of the projected population by selected age groups and sex for the United States: 2010 to 2050. Population Division 2008. http://www.census.gov/population/www/projections/summarytables. html. Accessed 22 November 2012.
2. Anderson G. Chronic care: making the case for ongoing care. Robert Wood Johnson Foundation, Princeton, NJ. http://www.rwjf.org/files/research/ 50968chronic.care.chartbook.pdf. Accessed 21 November 2012.
3. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. NCHS Data Brief 2010. http://www.cdc.gov/nchs/data/databriefs/db42.pdf. Accessed 22 November 2012.
4. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44-7.
5. Sabaté E. Adherence to long-term therapies: evidence for action. 2003. http://apps.who.int/medicinedocs/pdf/s4883e/s4883e.pdf. Accessed 20 November 2012.
6. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25(11):2958-71.
7. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
8. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drug Aging. 2004;21(12):793-811.
9. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Ann Intern Med. 1990;150(4):841-5.
10. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc. 2001;41(2):192-9.
11. Touchette DR, Burns AL, Bough MA, et al. Survey of medication therapy management programs under Medicare part D. J Am Pharm Assoc. 2006;46(6):683-91.
12. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6-14.
13. Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565-74.
14. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280-8.
15. Karve S, Cleves MA, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008;46(11):1125-33.
16. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11(7):453-60.
17. Steiner JF, Prochazka AV. The assessment of (re)fill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-16.
18. Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26(8):814-23.
19. Balkrishnan R, Bhosle MJ, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with overactive bladder syndrome: A longitudinal cohort study. J Urol. 2006;175(3):1067-72.
20. Krousel-Wood M, Islam T, Webber LS, et al. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15(1):59-66.
21. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007;10(1):3-12.
22. Ebbert JO, Dupras DM, Erwin PJ. Concise review for clinicians: searching the medical literature using PubMed: a tutorial. Mayo Clin Proc. 2003;78(1):87-91.
23. Barcenas CH, Zhang N, Zhao H, et al. Anthracycline regimen adherence in older patients with early breast cancer. Oncologist. 2012;17(3):303-11.
24. Conwell LJ, Esposito D, Garavaglia S, et al. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis. Am J Geriatr Pharmacother. 2011;9(4):241-9.
25. Curtis JR, Yun H, Matthews R, et al. Adherence with intravenous zoledronate and intravenous ibandronate in the United States medicare population. Arthritis Care Res. 2012;64(7):1054-60.
26. Donohue JM, Zhang Y, Aiju M, et al. Impact of Medicare Part D on antidepressant treatment, medication choice, and adherence among older adults with depression. Am J Geriatr Psychiatry. 2011;19(12):989-97.
27. Ettinger AB, Manjunath R, Candrilli SD, et al. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Epilepsy Behav. 2009;14(2):324-9.
28. Holmes HM, Luo R, Hanlon JT, et al. Ethnic disparities in adherence to antihypertensive medications of Medicare Part D beneficiaries. J Am Geriatr Soc. 2012;60(7):1298-303.
29. Jung K, McBean AM, Kim JA. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs. J Manag Care Pharm. 2012;18(2):106-15.
30. Kulik A, Shrank WH, Levin R, et al. Adherence to statin therapy in elderly patients after hospitalization for coronary revascularization. Am J Cardiol. 2011;107(10):1409-14.
31. Li P, McElligott S, Bergquist H, et al. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia. Ann Intern Med. 2012;156(11):776-84.
32. Patrick AR, Brookhart MA, Losina E, et al. The complex relation between bisphosphonate adherence and fracture reduction. J Clin Endocrinol Metab. 2010;95(7):3251-9.
33. Patrick AR, Schousboe JT, Losina E, et al. The economics of improving medication adherence in osteoporosis: validation and application of a simulation Model. J Clin Endocrinol Metab. 2011;96(9):2762-70.
34. Poon I, Lal LS, Ford ME, et al. Racial/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study. Ann Pharmacother. 2009;43(2):185-93.
35. Setoguchi S, Choudhry NK, Levin R, et al. Temporal trends in adherence to cardiovascular medications in elderly patients after hospitalization for heart failure. Clin Pharmacol Ther. 2010;88(4):548-54.
36. Solomon DH, Iversen MD, Avorn J, et al. Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med. 2012;172(6):477-83.
37. Stuart B, Simoni-Wastila L, Yin X, et al. Medication use and adherence among elderly Medicare beneficiaries with diabetes enrolled in Part D and retiree health plans. Med Care. 2011;49(5):511-5.
38. Swindle JP, Potash J, Kulakodlu M, et al. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin. Am J Geriatr Pharmacother. 2011;9(6):471-82.
39. Yang Y, Thumula V, Pace PF, et al. Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs. J Am Pharm Assoc. 2010;50(4):527-31.
40. Zeber JE, Copeland LA, Pugh MJV. Variation in antiepileptic drug adherence among older patients with new-onset epilepsy. Ann Pharmacother. 2010;44(12):1896-904.
41. Balkrishnan R, Christensen DB. A comparison of medication adherence indices to assess long-term inhaled corticosteroid medication use. J Asthma. 2001;38(1):91-8.
42. Bhosle MJ, Reardon G, Camacho FT, et al. Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population. Am J Geriatr Pharmacother. 2007;5(2):100-11.
43. Chapman RH, Petrilla AA, Benner JS, et al. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drug Aging. 2008;25(10):885-92.
44. Choudhry NK, Setoguchi S, Levin R, et al. Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients. Pharmacoepidemiol Drug Saf. 2008;17(12):1189-96.
45. Dickson M, Plauschinat CA. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. Am J Cardiovasc Drugs. 2008;8(1):45-50.
46. Huskamp HA, Deverka PA, Landrum MB, et al. The effect of three-tier formulary adoption on medication continuation and spending among elderly retirees. Health Serv Res. 2007;42(5):1926-42.
47. Jayawant SS, Bhosle MJ, Anderson RT, et al. Depressive symptomatology, medication persistence, and associated healthcare costs in older adults with glaucoma. J Glaucoma. 2007;16(6):513-20.
48. Keene MS, Eaddy MT, Nelson WW, et al. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders. Am J Manag Care. 2005;11(Suppl. 12):S362-9.
49. Kulkarni AS, Balkrishnan R, Anderson RT, et al. Medication adherence and associated outcomes in medicare health maintenance organization-enrolled older adults with Parkinson's disease. Mov Disord. 2008;23(3):359-65.
50. Mucha L, Shaohung S, Cuffel B, et al. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease. J Manag Care Pharm. 2008;14(5):451-61.
51. Winkelmayer WC, Levin R, Setoguchi S. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin J Am Soc Nephrol. 2008;3(5):1415-22.
52. Donohue JM, Zhang Y, Lave JR, et al. The Medicare drug benefit (Part D) and treatment of heart failure in older adults. Am Heart J. 2010;160(1):159-65.
53. Curtis JR, Westfall AO, Cheng H, et al. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction. Osteoporos Int. 2009;20(6):973-8.
54. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165(20):2414-9.
55. Roe CM, Anderson MJ, Spivack B. How many patients complete an adequate trial of donepezil? Alz Dis Assoc Dis. 2002;16(1):49-51.
56. Gellad WF, Grenard JL, Marcum ZA. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother. 2011;9(1):11-23.
57. Martin BC, Wiley-Exley EK, Richards S, et al. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36-44.
58. Choudhry NK, Shrank WH, Levin RL, et al. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15(7):457-64.
59. Jacobson G, Neuman T, Damico A, et al. Medicare Advantage plan star ratings and bonus payments in 2012. The Kaiser Family Foundation 2011. http://www.kff.org/medicare/upload/8257.pdf. Accessed 29 November 2012.
60. Centers for Medicare and Medicaid Services. Medicare health & drug plan quality and performance ratings 2012 Part C and Part D technical notes - first plan preview draft 2011. http://www.calquality.org/documents/Technical- Notes-2012.pdf. Accessed 29 November 2012.
61. Nau DP. Proportion of days covered (PDC) as a preferred method of measuring medication adherence: Pharmacy Quality Alliance 2011. http://www.pqaalliance.org/files/PDCvsMPRfinal.pdf. Accessed 30 November 2012.
62. Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care. 2001;10(2):42.